Study Summary
This study aims to evaluate the safety and feasibility of CTA101 in treating patients with relapsed or refractory CD19+ B-cell acute lymphoblastic leukemia.
Interested in this trial?
Submit an InquiryInterventions
CTA101BIOLOGICAL
Universal CD19-directed CAR-T cells by a single infusion intravenously will be given in escalating doses.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Affiliated hospital of Xuzhou medical college | Xuzhou | Jiangsu | China |